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Abstract
The Zika virus (ZIKV) epidemic in Brazil in 2015-2016 was followed by an increase in
the incidence of patients with Guillain-Barré syndrome (GBS). With this national sur-
vey study, we aimed to gain a better understanding of how neurologists in Brazil are
currently diagnosing and treating patients with GBS, and how this increase in inci-
dence has impacted the management of the disease. The questionnaire consisted of
52 questions covering: personal profile of the neurologist, practice of managing GBS
during and outside of the ZIKV epidemic, and limitations in managing GBS. All 3264
neurologists that were member of the Brazilian Academy of Neurology at the time of
the study were invited to participate. The questionnaire was fully answered by
171 (5%) neurologists. Sixty-one percent of neurologists noticed an increase in
patients with GBS during the ZIKV epidemic, and 30% experienced an increase in
problems in managing GBS during this time. The most important limitations in the
diagnosis and management of GBS included the availability of nerve conduction stud-
ies (NCS), beds in the Intensive Care Unit (ICU) and referral to rehabilitation centers.
Most neurologists did not use a protocol for treating patients with GBS and the treat-
ment practice varied. Increasing availability of NCS and beds in the ICU and rehabili-
tation centers, and the implementation of (inter)national guidelines, are critical in
supporting Brazilian neurologist in their management of GBS, and are especially
important in preparing for future outbreaks.
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1 | INTRODUCTION
Guillain-Barré syndrome (GBS) is the most common acute paralytic
neuropathy worldwide, with a global incidence of ~1-2 per 100 000
person-years.1 GBS typically presents as progressive weakness and
sensory signs, starting in the distal legs and progressing to the arms
and facial muscles.2 Disease progression is rapid and often severe,
with ~20% of patients requiring mechanical ventilation due to involve-
ment of respiratory muscles.2 Treatment for GBS generally consists of
multidisciplinary supportive medical care and immunotherapy. Both
intravenously administered immunoglobulin (IVIg) and plasma
exchange are proven effective therapies for GBS.3
GBS is an immune-mediated neuropathy and in most cases pre-
sumed to be triggered by specific types of infections.2 Several
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pathogens have been associated with GBS in case-control studies.4
Most recently, infection with Zika virus (ZIKV) was associated with
GBS, when incidence peaked during the outbreaks of ZIKV in Latin
America in 2015-2016.5,6 Brazil was one of the countries most
severely affected by the ZIKV epidemic, with ~370 000 cumulative
ZIKV cases (suspected or confirmed) reported by the World Health
Organization and Ministry of Health between December 2015 and
January 2018.7 The actual incidence is likely to be even higher, as
cases may have gone underreported, considering ZIKV usually causes
a mild and uncomplicated or subclinical infection. The number of
reported cases and the incidence in Brazil was highest in the North-
east, Southeast, and Center-West regions (Figure 1).8
It is unknown how neurologists in Brazil are currently managing
GBS and if the ZIKV epidemic has affected the diagnosis and treat-
ment of GBS patients. Apart from a protocol mainly directed to guide
clinicians in decisions on therapy, there are currently no detailed
national Brazilian guidelines for the diagnosis and management of
GBS, and at the time of the survey no international guidelines were
available.9 This may complicate the management of the syndrome,
especially because clinical presentation and disease progression can
differ extensively between patients and specific diagnostic or prog-
nostic markers for GBS are not yet available. Furthermore, it is
unknown if neurologists experience limitations in the availability of
diagnostic tools, treatment, or care for GBS, and if the increase of
GBS patients during the ZIKV epidemic affected such availability.
To gain a better understanding of the current clinical practice in
the management of GBS in Brazil and the impact of the ZIKV epi-
demic, we have conducted a national survey study among Brazilian
neurologists. With this survey, we identified limitations in the diagno-
sis and management of GBS in Brazil, both during and outside of out-
break periods. This information can help in developing strategies to
improve the clinical practice of GBS in Brazil, and to prepare for future
outbreaks of ZIKV or other pathogens that may trigger GBS.
2 | METHODS
2.1 | Ethical approval
This study was approved by the Ethical Review Board of the Ribeir~ao
Preto Medical School of the University of S~ao Paulo (FMRP-USP) and
the National Ethical Research Commission of Brazil (Comiss~ao
Nacional de Ética em Pesquisa, CONEP).
2.2 | Questionnaire
The questionnaire was developed by S.E.L., R.M.C., F.d.A.A.G., and
B.C.J., and was reviewed for consistency, readability, completeness, and
question sequencing by three independent GBS experts. Questions
were drafted in English and translated to Brazilian Portuguese by an
annotated translation agency. The questionnaire consists of
F IGURE 1 Number of reported
suspected Zika virus cases per state in
Brazil, 2016. This figure displays the
number of reported suspected ZIKV
cases in 2016 per state in Brazil, as
published by the Brazilian Ministry of
Health in in 2017.15 Not all cases
were laboratory confirmed, and other
arbovirus infections, were often not
excluded. Brazil is divided into
27 states and five regions. The five
regions are: North (AC, Acre; AP,
Amapá; AM, Amazonas; PA, Pará; RO,
Rondônia; RR, Roraima; TO, Tocatins),
Northeast (AL, Alagoas; BA, Bahía;
CE, Ceará; MA, Maranh~ao; PB,
Paraíba; PE, Pernambuco; PI, Piauí;
RN, Rio Grande do Norte; SE,
Sergipe), Center-West (GO, Goiás;
MT, Mato Grosso; MS, Mato Grosso
do Sul; DF, Distrito Federal),
Southeast (ES, Espírito Santo; MG,
Minas Gerais; RJ, Rio de Janeiro; SP,
S~ao Paulo), and South (PR, Paraná; RS,
Rio Grande do Sul; SC, Santa
Catarina)
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52 questions, with 41 multiple choice and 11 open-ended questions,
covering several topics, including: personal profile of the neurologist,
their practice of managing GBS during and outside of the ZIKV epidemic
and limitations they experience in managing GBS. The questionnaire
was distributed via an online platform (Limesurvey) that guarantees
anonymous and secure data storage and is approved by the Erasmus
University Medical Center for the conduction of survey studies.
2.3 | Study population
All the neurologists that were member of the Brazilian Academy of
Neurology (Academia Brasileira de Neurologia) were approached
through the Academy to participate in the survey study. They were
contacted via e-mail, containing a link to the online Limesurvey plat-
form. The first invitation was sent in February 2019 and participants
had a total of 70 days to answer the questionnaire. Five reminders
were sent during that time.
2.4 | Analysis
Statistical analysis of multiple-choice questions was done using IBM
SPSS Statistics 25 and included descriptive statistics and comparative
analyses (Chi square, Fisher's exact test). Two researchers (S.E.L. and
R.M.C) independently grouped open-ended questions into categories.
Discrepancies in interpretation were discussed to reach consensus.
3 | RESULTS
A total of 3264 neurologists were member of the Brazilian Academy
of Neurology at the start of the survey and were invited to participate
in the study. Of this group, 254 (8%) answered the questionnaire, and
of these responses, 171 (5%) were complete. For the analysis, only
fully completed questionnaires were used.
3.1 | Profile of the neurologists
The profile of the responding neurologists is described in Table 1. The
responders are well-varied regarding age, field of interest, and employ-
ment in the private vs public sector. The majority of neurologists work
in one hospital (49%), some in two (36%) and a few in three (15%).
Most neurologists work in hospitals in the city of S~ao Paulo (11%), Rio
de Janeiro (9%), Ribeir~ao Preto (6%), Belo Horizonte (6%), and Curitiba
(5%). Corresponding to this, responders most frequently work in the
Southeast region of Brazil (54%), followed by the South (18%), North-
east (17%), Center-Wester (8%) and North (3%) (Figure 2).
3.2 | Diagnosis
The clinical practice in diagnosis and treatment of GBS is shown in
Table 2. Criteria that were used for diagnosing GBS included the
criteria developed by the National Institute of Neurologic Diseases
and Stroke (NINDS) (1978, revised in 1990) and by the Brighton Col-
laboration (2010).10-12 Fifteen percent of the neurologists indicated
they used other criteria or no specific criteria.
According to most of the neurologists, cerebrospinal fluid (CSF)
testing was (almost) always indicated for diagnosing GBS, but only 4%
(almost) always tested CSF in suspected GBS cases. This discrepancy
may be explained in part by practical limitations in the opportunity to
examine CSF, which were experienced sometimes or frequently by
17% of neurologists (Figure 3). These limitations included the avail-
ability of laboratory testing (71%), personnel (33%), equipment (17%),
and high costs of the procedure (17%).
Nerve conduction studies (NCS) were available at the hospital of
57% of neurologists. Fifteen percent of the neurologists that indicated
NCS were not available at their hospital did not or could not always refer
the patient to a dedicated clinic. NCS were frequently or (almost) always
indicated in the diagnosis of GBS according to 77% of neurologists, but
fewer neurologists (66%) frequently or (almost) always made use of this
diagnostic tool (Figure 3). This may be explained by limitations in NCS,
that were frequently or (almost) always present in 36% of the
responders, and included limited availability of personnel (65%), equip-
ment (57%), high costs of the procedure (24%), and transportation issues
TABLE 1 Profile of responding neurologists (N = 171)
Age 40 (34-49)
Male: Female (ratio) 96:75 (1.28)
Years practicing as neurologist 10 (5-20)
Field of specialization or interest
General neurology 103 (64)
Neuromuscular disorders 60 (37)
Neuro-immunology 42 (26)
Vascular disorders 31 (19)
Movement disorders 30 (19)
Epilepsy 27 (17)
Neurodegenerative 26 (16)
Pediatric neurology 12 (7)
Neuro-oncology 5 (3)
Number of newly diagnosed GBS cases per year
0 4 (2)
1-5 98 (57)
6-10 50 (29)
11-20 14 (8)
>20 5 (3)
Affiliation in public and/or private hospital
Only public 49/156 (31)
Only private 64/156 (41)
Public and private 43/156 (28)
Note: Data are displayed as n/N (%), median (IQR) or n:n (ratio). For
questions with multiple answer formats, percentages do not add up
to 100.
Abbreviation: GBS, Guillain-Barré syndrome.
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(7%). Any limitations in CSF and NCS were experienced more often by
neurologists working in public hospitals vs those only working in private
hospitals, and those working in the Northeast and Center-West vs other
regions, although this was only significantly different for CSF examina-
tion (P = .04, respectively P < .001).
3.3 | Treatment and care
Most of the neurologists did not use a specific protocol to treat GBS
patients. Of the 64 neurologists who indicated to use a specific proto-
col, only seven provided details of this protocol. These protocols
included the Protocolo Clínico e Diretrizes Terapêuticas (PCDT), an
expert opinion protocol that is approved by the Ministry of Health of
Brazil; the American Academy of Neurology (AAN) Guideline on
immunotherapy for GBS; and the BMJ Best Practice guideline
on GBS.9
When asked what they consider to be the best treatment for
GBS, 60% of neurologists answered that IVIg and plasmapheresis are
equally effective, followed by 35% who considered IVIg to be the best
treatment. However, IVIg was the standard treatment for GBS in the
vast majority of responders. According to 48% of neurologists,
starting treatment is indicated in all GBS patients, regardless of clinical
presentation, severity or progression. When asked what the maximum
F IGURE 2 Geographic
distribution of responding
neurologists (N = 171). This figure
displays the number of responding
neurologists per state in Brazil
TABLE 2 Clinical practice of GBS diagnosis and treatment
Diagnostic criteria used
NINDS 71 (42)
Brighton Collaboration 98 (58)
Other or no specific/published criteriaa 29 (15)
Treatment protocol used 64/168 (38)
Treatment indication
All GBS patients are treated 81/171 (48)
Specific treatment indicationb
Rapid disease progression 80/90 (89)
Inability to walk independently (any distance) 69/90 (77)
Inability to walk independently for 10 m 13/90 (14)
(Imminent) respiratory insufficiency 76/90 (84)
Swallowing dysfunction 72/90 (80)
Severe autonomic dysfunction 72/90 (80)
Standard treatment (first line)
IVIg 162 (95)
PE 3 (2)
IVIG and IV corticosteroids (combination) 4 (2)
IVIg or PE 2 (1)
Alternative treatmentc (second line) 28/54 (52)
(Continues)
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time period was after the start of neurologic symptoms that they
would consider starting treatment in GBS patients, most indicated to
start treatment within 1 month (49%) or 2 weeks (23%), and 11% of
neurologists did not have any restrictions.
Although the preferred treatment was (almost) always available
for most responders, for 11% treatment was available only sometimes,
infrequently, very rarely or even never (Figure 4). When the preferred
treatment was not available, alternative treatment most often con-
sisted of plasmapheresis or IV corticosteroids. Reasons for limited
availability of the preferred treatment included high costs (55%), lim-
ited access to IVIg within the public health system (33%) and staff or
logistics-related issues (38%).
If a patient does not respond to treatment, 51% of neurologists
would switch to another treatment (eg, plasmapheresis if first treat-
ment was IVIg or vice-versa), 27% would repeat the same treatment,
and for 12% both repeating and switching therapy were an option. Of
the responders that would repeat treatment, 48% would repeat for a
maximum of two times, and 12% had no restrictions in how often
they would repeat treatment. Neurologists who indicated to have
expertise in neuro-immunology or neuromuscular diseases were more
likely to repeat treatment (P = .02), and less likely to switch treatment
(P < .001) compared to other neurologists. Treatment practice did not
significantly differ between neurologists who had more experience
(>5 years) or who saw more (≥5) GBS patients yearly.
Although an ICU was available in the hospital of 96% of neurolo-
gists, 55% experienced limitations in transferring GBS patients to the
ICU (Figure 4). A limited amount of beds at the ICU was the main
problem, indicated by 98% of the responders.
A rehabilitation program was available in the hospital of 77% of
the responders. If present, the program included physical therapy
(100%), speech therapy (86%), psychosocial support (60%), and occupa-
tional therapy (39%). Referral to a rehabilitation unit at discharge was
common, although a quarter of neurologists indicated that this was
done only sometimes, infrequently, or never or very rarely. Limitations
in referring patients to a rehabilitation unit were experienced by the
majority of responders, of which 36% experienced this frequently or
(almost) always (Figure 4). The most important limitations were a lack
of available beds (54%), no rehabilitation center in the region (25%),
and limited accessibility of rehabilitation for patients in the public
health sector (28%), including delay due to administrative procedures.
Neurologists working in the public sector more frequently experi-
enced any limitations in intensive care (P = .03) and referral to a reha-
bilitation unit (P = .03) compared to those only working in the private
sector. Any limitations in treatment and ICU availability were more
frequent in northern states, although this did not statistically differ
between regions.
3.4 | GBS during the ZIKV epidemic
During the ZIKV epidemic in Brazil, 61% of neurologists observed an
increase in admissions of patients with GBS in their hospital and 30%
of these neurologists experienced an increase in problems in the man-
agement of GBS patients. These increased problems included limita-
tions in the opportunity to perform NCS (68%) and CSF examination
(27%), availability of beds at the hospital (32%) and the ICU (59%), and
availability of treatment (41%). An increase in GBS patients during the
ZIKV epidemic was observed most often by neurologists working in the
Northeast of Brazil, and an increase in patients or problems in the man-
agement were less frequent in the southern regions (P < .05) (Figure 5).
At the time of answering the questionnaire, 59% of neurologists
tested for ZIKV in (selected) patients with GBS. Of these neurologists,
74% tested for ZIKV PCR, 73% for ZIKV IgM and only three neurolo-
gists indicated to use a plaque-reduction neutralization test.
4 | DISCUSSION
Neurologists in Brazil often experience limitations in the opportunity
to conduct NCS and to refer to the ICU and to rehabilitation centers
TABLE 2 (Continued)
PE 12/29 (41)
IV corticosteroids 6/29 (21)
Otherd 7/29 (24)
No response to treatment
Switch to other treatment 106 (62)
Repeat treatment 67 (39)
No additional treatment 13 (8)
Start corticosteroids 7 (4)
Othere 7 (4)
Indication ICU admissionb
Inability to walk independently (for any distance) 42 (25)
Inability to walk independently for ≥10 m 8 (5)
(Imminent) respiratory insufficiency 163 (95)
Rapid disease progression 142 (83)
Swallowing dysfunction 117 (68)
Severe autonomic dysfunction 147 (86)
Otherf 3 (2)
Note: Data are displayed as n/N (%) or median (IQR). For questions with
multiple answer formats, percentages do not add up to 100.
Abbreviations: NINDS, National Institute of Neurologic Diseases and
Stroke,11,12 Brighton, Brighton collaboration criteria;10 IVIg, intravenous
immunoglobulin; IV, intravenous; PE, plasma-exchange; ICU, Intensive
Care Unit.
aProtocolo Clínico e Diretrizes Terapêuticas (n = 5), American Academy of
Neurology Guideline on immunotherapy for GBS (n = 1), BMJ Best
Practice guideline for GBS (n = 1).
bMultiple answers were possible. Answer option “Inability to walk for any
distance” was considered mutually exclusive for “Inability to walk
for 10m.”.
cOnly neurologists that indicated that the preferred treatment was not
always available were asked this question.
dPE or corticosteroids (n = 3), PE or IVIg (n = 1), referral to other hospital
(n = 1), non-pharmaceutical support (n = 2).
eStart (intensive) rehabilitation (n = 2), depends on the individual patient
(n = 2), re-evaluation of diagnosis (n = 3).
fAll acute GBS cases (n = 2), clinical complications (n = 1).
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when confronted with patients with GBS. Most neurologists saw an
increase in GBS patients during the ZIKV epidemic, and one-third of
these neurologists also experienced an increase in problems in manag-
ing GBS patients during that time. The treatment practice of GBS of
neurologists in Brazil is comparable to treatment practice found in
other regions, and indicates that international guidelines are neces-
sary, especially to help deciding when to start and when to repeat
treatment in patients with GBS.13
Limitations in the diagnosis or treatment of GBS were experi-
enced frequently. Any limitations in NCS were experienced by 60%, in
F IGURE 4 Management: frequency and availability of treatment, ICU and rehabilitation. This figure shows how often neurologists
encountered limitations in the availability of the best treatment for GBS, ICU admission, and referral to a rehabilitation unit (“no limitations”), and
how often patients received in-hospital rehabilitation and were referred to a rehabilitation unit (“frequency”). For the variable “frequency referral
to rehabilitation center,” one responder used the answer option “other”
F IGURE 3 Diagnosis: indication, frequency, and availability of CSF and NCS. This figure displays how often neurologists considered CSF or
NCS to be indicated in the diagnosis of GBS (“indication”), how often they used these diagnostics tools (“frequency”), and how often they
encountered limitations in using these diagnostics (“no limitations”)
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ICU care by 55%, and in referring patients to a rehabilitation center by
~30% of neurologists. Especially the lack of availability of sufficient
intensive care for GBS patients is worrying, as this may directly affect
morbidity and even mortality of these patients. Limitations were gen-
erally more frequently experienced by neurologists working in the
Northeast and Center-West of Brazil, which corresponds to a lower
socioeconomic status in these regions, as reflected by regional contri-
bution to the gross domestic product.14 Both neurologists working at
the public and private sector experienced these limitations, but they
were more frequent in the public health system. So although the pub-
lic health system in Brazil (Sistema Único de Saúde) provides universal
health coverage for all inhabitants of the country, including access to
adequate treatment and care for GBS patients, our data indicate that
in practice, access is not guaranteed and often delayed, and that a lack
of availability of equipment, treatment, and beds in the ICU and reha-
bilitation centers occur frequently.
During the ZIKV outbreak in Brazil, about 60% of neurologists
experienced an increased frequency of GBS patients admitted to their
hospitals, about one-third of whom also experienced an increase in
problems managing GBS. Increase in patients with GBS was experi-
enced most frequently in the North, Northeast and Center-West of
Brazil, reflecting the areas that were subject to the highest incidence
of ZIKV during the outbreak in 2016.15 Limitations in availability of
NCS and ICU admission were again the biggest issues. Furthermore,
only 3% of neurologists indicated to use plaque-reduction neutraliza-
tion test in ZIKV, which is a laboratory test that helps to differentiate
between a recent ZIKV and dengue virus infection. Due to cross-reac-
tivity, ZIKV and dengue virus can be difficult to tell apart based on
serology, and implementation of this test can be crucial in correctly
diagnosing patients with ZIKV, especially when PCR results are nega-
tive.16,17 Lack of usage of this test suggests that identification of
ZIKV-related GBS cases may not be optimal.
Most neurologists do not use a specific protocol for treating GBS
patients, and in some situations the treatment practice varies between
neurologists or deviates from available evidence from treatment trials.
First, of the 29 neurologists that use an alternative treatment when
the preferred treatment (IVIg or plasmapheresis) for GBS is not avail-
able, about 20% use IV corticosteroids, although studies have proven
that corticosteroids are not effective in treating GBS and may even
have a negative effect on outcome.3 Second, about half of neurolo-
gists switch treatment and about a third repeat treatment in patients
that do not (sufficiently) respond to therapy, although no evidence
exists that this is effective. Third, about half of neurologists start
treatment in all patients with GBS, regardless of their clinical condi-
tion, although effectivity of plasmapheresis and IVIg has not been suf-
ficiently studied in patients still able to walk.18,19 This treatment
practice is also common outside of Brazil, and can likely be explained
by the lack of evidence and the absence of international guidelines for
treatment in these situations.13
This study has several limitations. First, the percentage of
responding neurologists was limited, and may be biased toward spe-
cific neurologists, for instance those working in the neuromuscular
field, in academic hospitals, or in certain regions. Second, the results
presented reflect the estimates and opinions of neurologists, that may
deviate from the actual practice.
5 | CONCLUSION
Increasing international migration of humans and vectors pose threats
of new epidemics of ZIKV or other arbovirus infections, potentially
related to GBS, resulting eventual upsurge of GBS incidence in the
near future.20 Our survey identified several critical limitations in the
current practice of managing GBS in Brazil and can direct the develop-
ment of strategies to improve this. Most importantly, the lack of avail-
ability of NCS, intensive care management and rehabilitation of GBS
should guide redistribution of available funding from the Brazilian
government or (inter)national nonprofit organizations. Furthermore,
F IGURE 5 Increase in GBS during
ZIKV epidemic displayed per state.
Increase in GBS patients during ZIKV
epidemic in Brazil (2015-2016) as
perceived by the responding neurologists
displayed as number of responders per
state, with percentage perceiving increase
per state
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treatment practice of GBS is variable and few neurologists use guide-
lines in treating patients with GBS. Increasing the visibility of the exis-
ting national expert opinion protocol for the management of GBS
(PCDT), or implementation of a recently published expert-based inter-
national guideline for the management of GBS may help to provide
such guidance.9,21
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